The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy
- PMID: 29068484
- DOI: 10.1111/ane.12840
The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy
Abstract
In natalizumab-treated patients without previous immunosuppressive treatment, the JCV antibody index is used to stratify PML risk. A high index value indicates that the risk to develop PML is significantly elevated, although probably about 99% of patients with this index value will not develop PML. This minireview aimed to provide an overview of the basic virology and immunology relevant to understanding JCV infections in MS patients, with a focus on what is presently known about antibodies to JCV and how they could be of use to predict and diagnose PML.
Keywords: JC virus; adaptive immune response; antibodies, antibody index; neuro-immune surveillance; progressive multifocal leukoencephalopathy.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.J Clin Virol. 2013 Jun;57(2):141-6. doi: 10.1016/j.jcv.2013.02.002. Epub 2013 Mar 5. J Clin Virol. 2013. PMID: 23465394
-
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.Neurology. 2012 May 29;78(22):1736-42. doi: 10.1212/WNL.0b013e3182583022. Epub 2012 May 16. Neurology. 2012. PMID: 22592369
-
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6. Mult Scler. 2015. PMID: 25662344
-
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.Mult Scler. 2018 Apr;24(5):563-573. doi: 10.1177/1352458517728814. Epub 2017 Aug 29. Mult Scler. 2018. PMID: 28847222 Review.
-
Advances in the management of PML: focus on natalizumab.Cleve Clin J Med. 2011 Nov;78 Suppl 2:S33-7. doi: 10.3949/ccjm.78.s2.08. Cleve Clin J Med. 2011. PMID: 22123933 Review.
Cited by
-
Seroprevalence of fourteen human polyomaviruses determined in blood donors.PLoS One. 2018 Oct 23;13(10):e0206273. doi: 10.1371/journal.pone.0206273. eCollection 2018. PLoS One. 2018. PMID: 30352098 Free PMC article.
-
Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis.J Infus Nurs. 2023 Nov-Dec 01;46(6):347-359. doi: 10.1097/NAN.0000000000000519. J Infus Nurs. 2023. PMID: 37920108 Free PMC article.
-
Biopsy-proven PML in an HIV-negative patient with discoid lupus: Failure to detect JC virus in CSF.Clin Neurol Neurosurg. 2021 Oct;209:106843. doi: 10.1016/j.clineuro.2021.106843. Epub 2021 Jul 27. Clin Neurol Neurosurg. 2021. PMID: 34461360 Free PMC article.
-
Training physicians in providing complex information to patients with multiple sclerosis: a randomised controlled trial.BMJ Open. 2022 Mar 15;12(3):e049817. doi: 10.1136/bmjopen-2021-049817. BMJ Open. 2022. PMID: 35292486 Free PMC article. Clinical Trial.
-
Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.Eur J Hosp Pharm. 2021 Mar;28(2):112-114. doi: 10.1136/ejhpharm-2019-002048. Epub 2019 Oct 16. Eur J Hosp Pharm. 2021. PMID: 33608441 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical